39 peer-reviewed studies · Evidence score: 8.5/10
Cho M et al. • The Australian and New Zealand journal of psychiatry (2019)
The comparative evaluation of efficacy and safety supported the use of anti-inflammatory adjuvant therapy over the use of antipsychotics alone.
Heringa SM et al. • Schizophrenia research (2015)
Estrogens and SERMs could be effective augmentation strategies in the treatment of women with schizophrenia, although potential side effects, partially associated with longer duration use, should be taken into account.
Thavaraputta S et al. • European journal of endocrinology (2023)
Women with anorexia nervosa have higher cortisol levels and lower DHEA-S and testosterone levels compared to women without anorexia nervosa.
Tiedt S et al. • Annals of neurology (2020)
A set of 4 metabolites with known biological effects relevant to stroke pathophysiology shows unprecedented utility to identify patients with IS upon hospital arrival, thus encouraging further investigation, including multicenter studies.
Çakici N et al. • Psychological medicine (2019)
Some, but not all agents with anti-inflammatory properties showed efficacy.
Komatsu Y et al. • Pharmacopsychiatry (2024)
Compared to the placebo, ulotaront, xanomeline/trospium chloride, vabicaserin, bitopertin, estradiol, cannabidiol, rimonabant, and D-serine showed efficacy for positive symptoms; roluperidone and pimavanserin were effective for negative symptoms; and encenicline, tropisetron, pregnenolone, tolcapone, BI 425809, and valacyclovir improved cognitive function.
Azietaku JT et al. • Journal of ethnopharmacology (2017)
In this paper, we have reviewed various researches conducted on N. incisum especially in areas of its ethnopharmacological use, phytochemicals, pharmacology and developed analytical methods.
Fountoulakis KN et al. • Psychiatrike = Psychiatriki (2016)
In this way there constitute new paradigms and open new horizons in the understanding of the disease.
Soria V et al. • Psychoneuroendocrinology (2018)
Positive trials were found for BD (mifepristone), MDD (dehydroepiandrosterone and fludrocortisone) and schizophrenia (dehydroepiandrosterone, raloxifene and pregnenolone).
Marx CE et al. • Journal of Clinical Psychopharmacology (2023)
Pregnenolone (500mg/day) significantly reduced PTSD symptom severity and improved functioning in military veterans.
Li R et al. • Journal of gynecology obstetrics and human reproduction (2022)
For steroid biosynthesis, early follicular phase LH levels help pregnenolone metabolize primarily via the ∆5 pathway in the GnRH antagonist stimulation protocol, but not via the ∆4 pathway.
Sakmar E et al. • Drug and alcohol dependence (2025)
These pilot findings suggest that PREG reduces cocaine craving and improves cocaine use outcomes in treatment seeking individuals with CUD, supporting further assessment of PREG in the treatment of CUD.
Ayatollahi A et al. • Clinical neuropharmacology (2020)
Pregnenolone adjunct to risperidone could attenuate core features associated with ASD.
Brown ES et al. • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2014)
The results suggest that pregnenolone may improve depressive symptoms in patients with BPD and can be safely administered.
Ritsner MS et al. • Psychiatry and clinical neurosciences (2014)
Thus, add-on pregnenolone reduces the severity of negative symptoms in recent-onset schizophrenia and schizoaffective disorder, especially among patients who are not treated with concomitant mood stabilizers.
Bosch E et al. • Human reproduction (Oxford, England) (2024)
No differences were observed for progesterone, estrone, 17-OH-progesterone, and pregnenolone in follicular fluid.
Barone JC et al. • Psychoneuroendocrinology (2023)
While preliminary and exploratory, our findings provide critical descriptive context for future studies.
Milivojevic V et al. • Psychopharmacology (2023)
Findings indicate that pregnenolone decreases stress- and alcohol cue-provoked craving and normalizes HPA axis and autonomic arousal in individuals with AUD, thereby supporting the need for further assessment of pregnenolone in the treatment of AUD.
Kardashev A et al. • Clinical schizophrenia & related psychoses (2018)
Pregnenolone with L-theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder.
Kashani L et al. • Journal of psychiatric research (2017)
No significant difference was found in the PANSS total score changes between the two arms (mean difference (CI 95%) = -9.41 (-20.24 to 1.41); p = 0.087).